Compare Quest Diagnostics Inc (DGX) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Quest Diagnostics Inc trades at $230.72 (market cap $25.48B), while Vanguard Total International Stock Index Fund ETF trades at $84.74 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 26.1× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Vanguard Total International Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| DGX | VXUS | |
|---|---|---|
Market Cap | $25.48B | $665.70B |
Volume | 941,866 | 4,864,744 |
Sector | Health | Sector/Thematic |
52-Week High | $247.45 | $88.41 |
52-Week Low | $173.49 | $72.17 |
Typical Hold Time | 56 Days | 55 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.
The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.
VXUS trades at $84.78, down 1.19% with a bearish technical signal from moving averages. The ETF provides broad international stock exposure outside the U.S., with institutional buying interest noted in recent SEC filings. Technical indicators show neutral oscillators but bearish momentum signals from ADX readings.
The fund offers diversification benefits as a core international holding, though recent performance faces headwinds. Key risks include currency fluctuations and emerging market volatility. Long-term outlook remains positive for global equity exposure, supported by Vanguard's low-cost structure and comprehensive market coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
